全文获取类型
收费全文 | 105279篇 |
免费 | 10381篇 |
国内免费 | 6418篇 |
专业分类
耳鼻咽喉 | 2124篇 |
儿科学 | 509篇 |
妇产科学 | 1740篇 |
基础医学 | 11199篇 |
口腔科学 | 3395篇 |
临床医学 | 7710篇 |
内科学 | 15383篇 |
皮肤病学 | 1987篇 |
神经病学 | 306篇 |
特种医学 | 4522篇 |
外国民族医学 | 122篇 |
外科学 | 16497篇 |
综合类 | 18648篇 |
现状与发展 | 23篇 |
预防医学 | 2508篇 |
眼科学 | 390篇 |
药学 | 5754篇 |
23篇 | |
中国医学 | 1739篇 |
肿瘤学 | 27499篇 |
出版年
2024年 | 54篇 |
2023年 | 1460篇 |
2022年 | 2399篇 |
2021年 | 3948篇 |
2020年 | 3691篇 |
2019年 | 3402篇 |
2018年 | 3232篇 |
2017年 | 3578篇 |
2016年 | 4128篇 |
2015年 | 4777篇 |
2014年 | 7398篇 |
2013年 | 6484篇 |
2012年 | 6562篇 |
2011年 | 6956篇 |
2010年 | 5633篇 |
2009年 | 5633篇 |
2008年 | 5905篇 |
2007年 | 6142篇 |
2006年 | 5733篇 |
2005年 | 5072篇 |
2004年 | 3936篇 |
2003年 | 3450篇 |
2002年 | 2955篇 |
2001年 | 2833篇 |
2000年 | 2445篇 |
1999年 | 1911篇 |
1998年 | 1602篇 |
1997年 | 1436篇 |
1996年 | 1311篇 |
1995年 | 1204篇 |
1994年 | 1093篇 |
1993年 | 764篇 |
1992年 | 671篇 |
1991年 | 606篇 |
1990年 | 509篇 |
1989年 | 451篇 |
1988年 | 402篇 |
1987年 | 329篇 |
1986年 | 267篇 |
1985年 | 296篇 |
1984年 | 233篇 |
1983年 | 172篇 |
1982年 | 207篇 |
1981年 | 171篇 |
1980年 | 174篇 |
1979年 | 154篇 |
1978年 | 99篇 |
1977年 | 74篇 |
1976年 | 65篇 |
1975年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
102.
103.
Ragnhild B. Wijma Marloes Emous Merel van den Broek Anke Laskewitz Anneke C. Muller Kobold André P. van Beek 《Surgery for obesity and related diseases》2019,15(1):73-81
Background
Early dumping is a poorly defined and incompletely understood complication after Roux-en-Y gastric (RYGB).Objective
We performed a mixed-meal tolerance test in patients after RYGB to address the prevalence of early dumping and to gain further insight into its pathophysiology.Setting
The study was conducted in a regional hospital in the northern part of the Netherlands.Methods
From a random sample of patients who underwent primary RYGB between 2008 and 2011, 46 patients completed the mixed-meal tolerance test. The dumping severity score for early dumping was assessed every 30 minutes. A sum score at 30 or 60 minutes of ≥5 and an incremental score of ≥3 points were defined as indicating a high suspicion of early dumping. Blood samples were collected at baseline, every 10 minutes during the first half hour, and at 60 minutes after the start.Results
The prevalence of a high suspicion of early dumping was 26%. No differences were seen for absolute hematocrit value, inactive glucagon-like peptide-1, and vasoactive intestinal peptide between patients with or without early dumping. Patients at high suspicion of early dumping had higher levels of active glucagon-like peptide-1 and peptide YY.Conclusion
The prevalence of complaints at high suspicion of early dumping in a random population of patients after RYGB is 26% in response to a mixed-meal tolerance test. Postprandial increases in both glucagon-like peptide-1 and peptide YY are associated with symptoms of early dumping, suggesting gut L-cell overactivity in this syndrome. 相似文献104.
105.
106.
107.
Neil Ryan Johanna Wall Emma J Crosbie Mark Arends Tjalling Bosse Saimah Arif Asma Faruqi Ian Frayling Raji Ganesan Ye L Hock Raymond McMahon Ranjit Manchanda W Glenn McCluggage Pinias Mukonoweshuro Gerhard van Schalkwyk Lucy Side John H Smith Bruce Tanchel D Gareth Evans C Blake Gilks Naveena Singh 《Histopathology》2019,75(6):813-824
108.
109.
Haonan Guo Rui Zhang Justice Afrifa Yuanyuan Wang Jingcui Yu 《Pathology, research and practice》2019,215(6):152403
PurposeWe previously demonstrated that the functional inactivation of DAL-1 and TOB1 promotes an aggressive phenotype in gastric cancer cells, but the links between both genes and the survival of patients with gastric cancer are unknown. Here, we investigated the correlations of the expression levels of DAL-1 and TOB1 with the progression of gastric cancer.MethodsA total of 270 patients who underwent resectable gastrectomy were included. The expression of DAL-1 and TOB1 was detected by immunohistochemistry.ResultsLow expression of DAL-1 in cancer tissue was significantly associated with tumor site (p < 0.05), histological grade (p < 0.01), depth of invasion (p < 0.05), lymph node metastasis status (p < 0.05), Lauren classification (p < 0.001), and clinical stage (p < 0.01). A lower level of TOB1 was observed in gastric cancer patients with diffuse type disease compared to patients with either intestinal or mixed type disease (p < 0.001). Additionally, Spearman’s correlation analysis revealed that decreased expression of DAL-1 was positively correlated with low TOB1 expression (r=0.304, p < 0.001). The survival analysis showed that low levels of DAL-1 and TOB1 were significantly associated with poor survival of gastric cancer patients (p <0.001 and p < 0.05, respectively).ConclusionThe downregulation of DAL-1 and TOB1 expression is associated with shorter survival of gastric cancer patients. Hence, DAL-1 and TOB1 may be considered potential novel markers for predicting the outcomes of patients with gastric cancer. 相似文献
110.
The pituitary tumor-transforming gene 1 (PTTG1), also known as Securin, is considered an oncogene. This study aimed to investigate the role of PTTG1 in clear cell renal cell carcinoma (ccRCC) using in silico bioinformatics approaches. A pan-cancer analysis using The Cancer Genome Atlas (TCGA) data indicated that among all cancer types copy number amplification of PTTG1 gene was most frequently found in ccRCC. However, amplification of PTTG1 gene copy number did not correlate with the increase of mRNA level in ccRCC, and did not predict the patients' overall survival. Instead, ccRCC was correlated with overexpression of PTTG1 mRNA, and its expression level was stage-dependent increased in cancer patients. An outlier analysis using the Oncomine database suggested that PTTG1 mRNA expression served as a good biomarker for ccRCC. Pathway analysis for upregulated genes enriched in PTTG1-high expressing ccRCC patients found that PTTG1 overexpression was associated with mitotic defects. Mining drug sensitivity data using the Cancer Therapeutics Response Portal (CTRP) discovered that PTTG1-high expressing ccRCC cell lines were susceptible to a Rac1 (Ras-related C3 botulinum toxin substrate 1) inhibitor NSC23766. Therefore, this study provides an in silico insight into the role of PTTG1 in ccRCC, and repurposes the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing ccRCC. 相似文献